- Home
- RELX vs GNLX Comparison
RELX vs GNLX Comparison
Compare RELX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELX
- GNLX
- Stock Information
- Founded
- RELX 1903
- GNLX 2001
- Country
- RELX United Kingdom
- GNLX United States
- Employees
- RELX N/A
- GNLX N/A
- Industry
- RELX Business Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RELX Consumer Discretionary
- GNLX Health Care
- Exchange
- RELX Nasdaq
- GNLX Nasdaq
- Market Cap
- RELX 97.3B
- GNLX 109.4M
- IPO Year
- RELX N/A
- GNLX 2023
- Fundamental
- Price
- RELX $53.88
- GNLX $3.38
- Analyst Decision
- RELX Strong Buy
- GNLX Strong Buy
- Analyst Count
- RELX 2
- GNLX 4
- Target Price
- RELX N/A
- GNLX $17.75
- AVG Volume (30 Days)
- RELX 852.9K
- GNLX 153.5K
- Earning Date
- RELX 07-25-2025
- GNLX 08-13-2025
- Dividend Yield
- RELX 1.12%
- GNLX N/A
- EPS Growth
- RELX 10.15
- GNLX N/A
- EPS
- RELX 1.29
- GNLX N/A
- Revenue
- RELX $11,810,658,884.00
- GNLX N/A
- Revenue This Year
- RELX $9.12
- GNLX N/A
- Revenue Next Year
- RELX $7.22
- GNLX N/A
- P/E Ratio
- RELX $40.66
- GNLX N/A
- Revenue Growth
- RELX 2.98
- GNLX N/A
- 52 Week Low
- RELX $43.45
- GNLX $1.60
- 52 Week High
- RELX $56.33
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- RELX 48.69
- GNLX 65.71
- Support Level
- RELX $52.11
- GNLX $2.80
- Resistance Level
- RELX $54.30
- GNLX $3.61
- Average True Range (ATR)
- RELX 0.45
- GNLX 0.22
- MACD
- RELX 0.04
- GNLX 0.05
- Stochastic Oscillator
- RELX 53.10
- GNLX 80.23
About RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.